OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Garcia on the Role of Navitoclax in Myelofibrosis

February 21st 2020

Jacqueline S. Garcia, MD,discusses how navitoclax differs from other agents in primary or secondary myelofibrosis.

Dr. Danilov on ELEVATE-TN Trial Results in CLL

February 21st 2020

Alexey V. Danilov, MD, PhD, discusses the findings of the phase III ELEVATE-TN trial in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Fendler on Clinical Need for 68GA-PSMA-11 PET in Prostate Cancer

February 21st 2020

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.

Dr. Emens on Combining Checkpoint Inhibitors With PARP Inhibitors in Ovarian Cancer

February 21st 2020

Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.

Dr. Cercek on Targeted Strategies in BRAF-Mutant mCRC

February 21st 2020

Andrea Cercek, MD, discusses targeted strategies in BRAF-mutant metastatic colorectal cancer.

Dr. Lopategui on the Use of Liquid Biopsies in Lung Cancer

February 21st 2020

Jean Lopategui, MD, discusses the use of liquid biopsies in lung cancer.

Dr. Denduluri on the Use of the Oncotype DX Assay in Early-Stage HR+/HER2- Breast Cancer

February 21st 2020

Neelima Denduluri, MD, discusses the use of the Oncotype DX assay in early-stage hormone receptor–positive, HER2-negative breast cancer.

Dr. Graff on the KEYNOTE-199 Trial Design in Castration-Resistant Prostate Cancer

February 20th 2020

Julie N. Graff, MD, discusses the multi-cohort, phase II KEYNOTE-199 study examining patients with metastatic castration-resistant prostate cancer.

Dr. Woyach on Ibrutinib Regimens in Frontline CLL

February 20th 2020

Jennifer Woyach, MD, discusses the findings of the ALLIANCE AO41202 and ECOG-ACRIN E1912 trials in the frontline treatment for patients with chronic lymphocytic leukemia.

Dr. Eng on Increasing Awareness for Adolescents/Young Adults With CRC

February 20th 2020

Cathy Eng, MD, FACP, FASCO, discusses the need to increase awareness regarding treating adolescents and young adults with colorectal cancer.

Dr. Mirhadi on Novel Radiation Technologies in NSCLC

February 20th 2020

Amin J. Mirhadi, MD, discusses novel radiation approaches that are being used in non–small cell lung cancer.

Dr. Mita on Emergence of Checkpoint Inhibitors SCLC

February 20th 2020

Alain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.

Dr. Chon on Challenges With Maintenance Therapy in Ovarian Cancer

February 20th 2020

Hye Sook Chon, MD, gynecologic oncologist, Moffitt Cancer Center, discusses challenges that are still faced in the maintenance setting in advanced ovarian cancer.

Dr. Penson on Biomarkers of Response to PARP Inhibitors in Ovarian Cancer

February 20th 2020

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Medicine, Massachusetts General Hospital, discusses prospective biomarkers that may predict response to PARP inhibitors in advanced ovarian cancer.

Dr. Hoffman on Primary Debulking Versus Neoadjuvant Chemotherapy in Ovarian Cancer

February 20th 2020

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses eligibility criteria for primary debulking surgery versus neoadjuvant chemotherapy in advanced ovarian cancer.

Dr. Husain on Liquid Biopsy Versus Tissue Biopsy in NSCLC

February 20th 2020

Hatim Husain, MD, discusses the utility of liquid biopsy versus tissue biopsy in non–small cell lung cancer.

Dr. Luke on Predictive Biomarkers in Metastatic Melanoma

February 20th 2020

Jason J. Luke, MD, FACP, discusses predictive biomarkers in metastatic melanoma.

Dr. Levy on Repeat Testing in NSCLC

February 20th 2020

Benjamin P. Levy, MD, discusses the importance of repeat testing in non–small cell lung cancer.

Dr. Pal on the Rationale for Adding Cabozantinib to Atezolizumab in Prostate Cancer

February 19th 2020

Sumanta K. Pal, MD, discusses the rationale for adding cabozantinib to atezolizumab in prostate cancer.

Dr. Pennell on Considerations for Immediate Treatment in Lung Cancer

February 19th 2020

Nathan A. Pennell, MD, PhD, discusses the considerations when choosing therapy for patients with lung cancer who need immediate therapy but have not received the results of their molecular testing.